In September 2016, anwas sent to professionals who specialise in the treatment of epilepsy to inform them of the withdrawal of retigabine (Trobalt) from the market in June 2017. This product is being discontinued because of limited and declining use.
The letter outlines advice for healthcare providers to begin seeking alternative treatment for affected patients, and to withdraw treatment with a gradual dose reduction over at least 3 weeks. No new patients should start retigabine treatment.
In September 2016, letters were also sent for the following medicines:
, and off-label use in children younger than age 5 years. See also and dosing aids
Article citation: Drug Safety Update volume 10 issue 3, October 2016: 2.